VALET-CMV: Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant (clinicaltrials.gov) - Jul 25, 2025 - P2/3 | N=150 | Recruiting | Sponsor: Columbia University
New P2/3 trial • Cytomegalovirus Infection • Infectious Disease • Neutropenia • Transplant Rejection • Transplantation
|